nang2
SENIOR MEMBER
![](/styles/default/xenforo/ranks/Brigadier.jpg)
- Joined
- Dec 14, 2015
- Messages
- 5,742
- Reaction score
- 2
- Country
- Location
![www.fiercebiotech.com](/proxy.php?image=https%3A%2F%2Fqtxasset.com%2Fquartz%2Fqcloud5%2Fmedia%2Fimage%2Ffiercebiotech%2F1636112595%2FGettyImages-1293456793.jpg%2FGettyImages-1293456793.jpg%3FVersionId%3Dxpa4sfJAR2lVrZXeUzKc6LmNmPWZ9a2x&hash=24d5ac68b77648a1e6e40250d6533ff4&return_error=1)
UPDATE: Pfizer's oral COVID-19 antiviral cuts hospitalization, death by 89%, sending team barreling to FDA
Pfizer’s oral COVID-19 antiviral Paxlovid has cut the risk of | Pfizer’s oral COVID-19 antiviral has cut the risk of hospitalization or death by 89% in a late-phase trial, prompting the Big Pharma to stop the study and race to seek emergency use authorization from the FDA.
@Tai Hai Chen This may particularly interest you.